Evidence map›Paper›PMID 34401362›Full record

ArticleToxicology reports2021

Acute toxicity evaluation of a novel ceramide analog for the treatment of breast cancer.

Tulasi Ponnapakkam, Kyla Bongay-Williams, Teresa Beamon, Royce Hooks, Degrick Cheatham, Navneet Goyal, Muralidharan Anbalagan, Maryam Foroozesh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxicology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Tulasi PonnapakkamDepartment of Chemistry, Xavier University of Louisiana, 1 Drexel Dr., New Orleans, LA 70125, USA.
Kyla Bongay-WilliamsDepartment of Chemistry, Xavier University of Louisiana, 1 Drexel Dr., New Orleans, LA 70125, USA.
Teresa BeamonDepartment of Chemistry, Xavier University of Louisiana, 1 Drexel Dr., New Orleans, LA 70125, USA.
Royce HooksDepartment of Chemistry, Xavier University of Louisiana, 1 Drexel Dr., New Orleans, LA 70125, USA.
Degrick CheathamDepartment of Chemistry, Xavier University of Louisiana, 1 Drexel Dr., New Orleans, LA 70125, USA.
Navneet GoyalDepartment of Chemistry, Xavier University of Louisiana, 1 Drexel Dr., New Orleans, LA 70125, USA.
Muralidharan AnbalaganDepartment of Structural and Cellular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Maryam ForoozeshDepartment of Chemistry, Xavier University of Louisiana, 1 Drexel Dr., New Orleans, LA 70125, USA.
Xavier University of Louisiana · USTulane University · US

Funding

Xavier RCMI Renewal Application-Research Infrastructure CoreU54MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI Sara Abdul Sattar Al-Dahir · 2019 to 2026
$41.9M
Xavier's RCMI Cancer Research ProgramG12MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI D'AMOUR, GENE, WANG, GUANGDI · 2012 to 2018
$15.7M
PROJECT PATHWAYS: STUDENT TRAINING CORETL4GM118968 · NIGMS · XAVIER UNIVERSITY OF LOUISIANA · PI FOROOZESH, MARYAM, GIGUETTE, MARGUERITE · 2015 to 2023
$9.2M
Project Pathways: Research Enrichment CoreRL5GM118966 · NIGMS · XAVIER UNIVERSITY OF LOUISIANA · PI FOROOZESH, MARYAM, GIGUETTE, MARGUERITE · 2015 to 2023
$6.6M
Ceramides for Breast Cancer TreatmentR15CA242991 · NCI · XAVIER UNIVERSITY OF LOUISIANA · PI FOROOZESH, MARYAM · 2019 to 2019
$408k
Multi-Target, Mechanism-Based Drug Design for the Treatment of Breast Cancer: SynR15CA159059 · NCI · XAVIER UNIVERSITY OF LOUISIANA · PI FOROOZESH, MARYAM · 2011 to 2011
$370k
NCI NIH HHS R15 CA159059NCI NIH HHS R15 CA242991NIGMS NIH HHS RL5 GM118966NIGMS NIH HHS TL4 GM118968NIMHD NIH HHS U54 MD007595
6 · The paper itself

Abstract

We have previously reported that treating triple-negative tumor bearing nude mice with intraperitoneal (ip) 10 mg/kg body weight of (S,E)-3-hydroxy-2-(2-hydroxybenzylidene)amino

Indexed as

Biochemical parametersBreast cancerCeramideDrugToxicology

Identifiers

PMID34401362
PMCPMC8355835
OpenAlexW3188115218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.